Abstract
Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C- aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (t0), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 ± 5.4, t 8 = 13.5 ± 4.0, t38 = 16.1 ± 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 ± 1.1, t 8 = 2.4 ± 0.8, t38 = 2.6 ± 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 1207-1213 |
| Number of pages | 7 |
| Journal | Digestive Diseases and Sciences |
| Volume | 50 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2005 |
Fingerprint
Keywords
- C-aminopyrine breath test
- Clarithromycin
- Helicobacter pylori
- Liver function
- Metronidazole
- Rabeprazole
ASJC Scopus subject areas
- Gastroenterology
Cite this
Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test. / Giannini, Edoardo G.; Malfatti, Federica; Botta, Federica; Polegato, Simone; Testa, Emanuela; Fumagalli, Alessandra; Mamone, Mario; Savarino, Vincenzo; Testa, Roberto.
In: Digestive Diseases and Sciences, Vol. 50, No. 7, 07.2005, p. 1207-1213.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test
AU - Giannini, Edoardo G.
AU - Malfatti, Federica
AU - Botta, Federica
AU - Polegato, Simone
AU - Testa, Emanuela
AU - Fumagalli, Alessandra
AU - Mamone, Mario
AU - Savarino, Vincenzo
AU - Testa, Roberto
PY - 2005/7
Y1 - 2005/7
N2 - Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C- aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (t0), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 ± 5.4, t 8 = 13.5 ± 4.0, t38 = 16.1 ± 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 ± 1.1, t 8 = 2.4 ± 0.8, t38 = 2.6 ± 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.
AB - Helicobacter pylori eradication therapy is commonly prescribed in the general population. Treatment consists of drugs that are mainly metabolized by the liver cytochrome P-450 (CYP) enzymatic pool. Most H. pylori-infected patients often take drugs for comorbid illnesses, therefore increasing the potential for drug-drug interactions. We aimed to evaluate the interactions of rabeprazole, clarithromycin, and metronidazole 1-week H. pylori eradication therapy with CYP-dependent liver metabolic function in clinical practice. Ten patients referred to our unit for H. pylori infection underwent 1-week eradication therapy with rabeprazole (20 mg, b.i.d.), clarithromycin (500 mg, b.i.d.), and metronidazole (500 mg, b.i.d.). We chose the 13C- aminopyrine breath test (13C-ABT) to evaluate CYP-dependent liver function since it is noninvasive and nonharmful. All patients underwent 13C-ABT at three time points: before therapy (t0), at the end of therapy (t8), and after 1 month of follow-up (t38). Mean 13C-ABT dose/hr (t0 = 14.0 ± 5.4, t 8 = 13.5 ± 4.0, t38 = 16.1 ± 5.6) as well as 13C-ABT cumulative dose (t0 = 2.4 ± 1.1, t 8 = 2.4 ± 0.8, t38 = 2.6 ± 1.0) were not statistically different at the three time points of the study. These results did not seem to be influenced by drugs being administered concomitantly. In everyday clinical practice rabeprazole-based H. pylori eradication therapy does not seem to display any significant interactions with CYP-dependent liver function, even in patients on multiple drugs.
KW - C-aminopyrine breath test
KW - Clarithromycin
KW - Helicobacter pylori
KW - Liver function
KW - Metronidazole
KW - Rabeprazole
UR - http://www.scopus.com/inward/record.url?scp=23044463770&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23044463770&partnerID=8YFLogxK
U2 - 10.1007/s10620-005-2761-z
DO - 10.1007/s10620-005-2761-z
M3 - Article
C2 - 16047461
AN - SCOPUS:23044463770
VL - 50
SP - 1207
EP - 1213
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
SN - 0163-2116
IS - 7
ER -